Initial estradiol response predicts outcome of exogenous gonadotropins using a step-down dose regimen for induction of ovulation in polycystic ovary syndrome.

To study ovarian stimulation and response patterns during a gonadotropin step-down dose regimen for induction of ovulation by applying a decremental dose regimen in polycystic ovary syndrome (PCOS) patients.
The present prospective study involves 28 infertile clomiphene citrate-resistant PCOS patients during gonadotropin-induced cycles using a modified step-down dose regimen (and adjuvant GnRH agonist medication). Applied gonadotropin doses included initial daily doses of 150 IU IM followed by two reducing steps (37.5 IU each) based on sonographic criteria to a final daily dose of 75 IU IM.
Anovulatory infertile women in an academic referral center.
Daily blood withdrawal and transvaginal pelvic ultrasound.
Serum FSH and E2 concentration and follicle growth were investigated daily during gonadotropin administration.
An initial 2.1-fold increase in serum FSH levels was observed followed by a subsequent decrease of 10% (median) per day for 4 days. Growth of ovarian follicles was sustained and ovulation achieved (midluteal P, 11.7 +/- 1.3 ng/mL; conversion factor to SI unit, 3.180; mean +/- SD) in 22 patients. Major variability in day 3 E2 increase (range, 67 to 866 pg/mL; conversion factor to SI unit, 3.671)--not related to differences in FSH serum concentrations and without changes in follicle number and size--suggests differences in ovarian sensitivity for FSH stimulation. A strong correlation (r = 0.82) was found between day 3 E2 increase and the chance of ovulation. Moreover, E2 levels on the day of gonadotropin dose reduction predict (r = 0.68) chances of late follicular phase E2 levels exceeding 871 pg/mL (conversion factor to SI value, 3.671).
These findings provide the endocrine basis for the concept of gonadotropin induction of ovulation using a step-down dose regimen. Initial E2 increase (before initiation of follicle growth) represent differences in ovarian sensitivity to gonadotropins and predict treatment outcome.
AuthorsD C Schoot, W C Hop, F H de Jong, T J van Dessel, B C Fauser
JournalFertility and sterility (Fertil Steril) Vol. 64 Issue 6 Pg. 1081-7 (Dec 1995) ISSN: 0015-0282 [Print] UNITED STATES
PMID7589656 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Chorionic Gonadotropin
  • Estradiol
  • Menotropins
  • Follicle Stimulating Hormone
  • Buserelin
  • Buserelin (therapeutic use)
  • Chorionic Gonadotropin (therapeutic use)
  • Estradiol (blood)
  • Female
  • Follicle Stimulating Hormone (administration & dosage, blood, therapeutic use)
  • Humans
  • Infertility, Female (therapy)
  • Menotropins (therapeutic use)
  • Ovulation Induction
  • Polycystic Ovary Syndrome (physiopathology)
  • Prospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: